1,319 Amgen Inc. $AMGN Shares Sold by Godsey & Gibb Inc.

Godsey & Gibb Inc. trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 1.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 70,261 shares of the medical research company’s stock after selling 1,319 shares during the period. Amgen comprises 2.0% of Godsey & Gibb Inc.’s portfolio, making the stock its 14th biggest holding. Godsey & Gibb Inc.’s holdings in Amgen were worth $29,616,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Wellington Altus USA Inc. lifted its stake in shares of Amgen by 72.3% in the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after purchasing an additional 34 shares during the period. Tower View Wealth Management LLC grew its position in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after buying an additional 63 shares during the period. Security National Bank of Sioux City Iowa IA bought a new stake in Amgen during the second quarter valued at approximately $36,000. Steph & Co. bought a new stake in Amgen during the third quarter valued at approximately $42,000. Finally, Evergreen Advisors LLC bought a new stake in Amgen during the first quarter valued at approximately $37,000. 76.50% of the stock is currently owned by institutional investors.

Insider Activity

In related news, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the sale, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 6,222 shares of company stock valued at $2,540,926 in the last quarter. 0.85% of the stock is currently owned by company insiders.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis. Nearly 70% of patients receiving the higher dose achieved remission after 24 weeks, strengthening the drug’s expansion opportunity in a condition with limited approved treatments. What Could Amgen (AMGN) 70% Remission Trial Result Mean For Its Pipeline?
• Positive Sentiment: UBS raised its price target for Amgen to $470, signaling increased confidence in the company’s earnings and pipeline outlook. Cantor Fitzgerald also recently lifted its target to $440. UBS raises target for Amgen stock to USD 470.00 Cantor Fitzgerald raised target for Amgen stock to USD 440
• Positive Sentiment: Investors are also focusing on Amgen’s broader growth prospects, including planned Phase 3 studies for obesity drug candidate MariTide, continued manufacturing investment, and the European Union authorization of Jascayd. These developments reinforce expectations for future product launches and portfolio expansion. Amgen Gains as Investors Appear to Lean on Pipeline and Regulatory Momentum
• Positive Sentiment: Erste Group raised its FY2027 earnings-per-share estimate to $24.66 from $24.36, above Amgen’s current-year consensus estimate of $22.94. The revision suggests some analysts expect continued earnings growth.
• Neutral Sentiment: A new Phase 1 study is evaluating an alternative delivery approach for Evenity. The study could support product optimization, but it is early-stage and unlikely to materially affect near-term results. Amgen Fine-Tunes Evenity Delivery in New Phase 1 Study
• Negative Sentiment: Bank of America Securities continues to rate Amgen a Sell, providing a counterweight to the recent target increases and highlighting continued valuation or execution concerns. Bank of America Securities Remains a Sell on Amgen
• Negative Sentiment: Amgen insiders reported seven open-market sales and no purchases over the past six months. While these transactions are not necessarily company-specific signals, the absence of insider buying may temper bullish sentiment.

Amgen Stock Up 3.2%

AMGN opened at $426.11 on Thursday. The stock has a market cap of $230.37 billion, a price-to-earnings ratio of 18.45, a price-to-earnings-growth ratio of 3.02 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The firm’s fifty day moving average is $414.53 and its 200 day moving average is $373.75. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $447.03.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. Amgen’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, sell-side analysts forecast that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a $2.52 dividend. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.4%. Amgen’s dividend payout ratio is 62.65%.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Piper Sandler increased their price target on shares of Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. Scotiabank lifted their price target on shares of Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a research note on Monday, September 28th. Barclays boosted their price objective on shares of Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a research report on Friday, August 14th. Weiss Ratings upgraded Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Finally, Sanford C. Bernstein upped their price objective on Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $387.93.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.